Similar articles for PMID: 32366395

Year	Number of Results
2012	1
2013	1
2014	6
2015	7
2016	14
2017	20
2018	34
2019	40
2020	44
2021	28
2022	19
2023	4
2024	0

1

A Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft (PDOX) Mouse Model Is Sensitive to Bevacizumab and Vinorelbine, Regressed by Eribulin and Resistant to Olaparib.

Yamamoto J, Murata T, Tashiro Y, Higuchi T, Sugisawa N, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Hongo A, Nomura T, Saitoh W, Moriya T, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM. Yamamoto J, et al. Anticancer Res. 2020 May;40(5):2509-2514. doi: 10.21873/anticanres.14221. Anticancer Res. 2020. PMID: 32366395

2

Eribulin Regresses a Cisplatinum-resistant Rare-type Triple-negative Matrix-producing Breast Carcinoma Patient-derived Orthotopic Xenograft Mouse Model.

Yamamoto J, Murata T, Sugisawa N, Higuchi T, Tashiro Y, Nishino H, Inubushi S, Sun YU, Lim H, Miyake K, Shimoya K, Nomura T, Kurebayashi J, Tanino H, Hozumi C, Bouvet M, Singh SR, Endo I, Hoffman RM. Yamamoto J, et al. Anticancer Res. 2020 May;40(5):2475-2479. doi: 10.21873/anticanres.14217. Anticancer Res. 2020. PMID: 32366391

3

A Case of Rare Matrix-producing Triple-negative Breast Carcinoma for Which Drug Response in a Patient-derived Orthotopic Xenograft Mouse Model Was Correlated With Patient Response.

Nomura T, Kurebayashi J, Moriya T, Saito W, Murata T, Yamamoto J, Hozumi C, Hoffman RM. Nomura T, et al. Anticancer Res. 2021 Dec;41(12):6191-6197. doi: 10.21873/anticanres.15438. Anticancer Res. 2021. PMID: 34848473

4

A Single Low Dose of Eribulin Regressed a Highly Aggressive Triple-negative Breast Cancer in a Patient-derived Orthotopic Xenograft Model.

Lim HI, Yamamoto J, Inubushi S, Nishino H, Tashiro Y, Sugisawa N, Han Q, Sun YU, Choi HJ, Nam SJ, Kim MB, Lee JS, Hozumi C, Bouvet M, Singh SR, Hoffman RM. Lim HI, et al. Anticancer Res. 2020 May;40(5):2481-2485. doi: 10.21873/anticanres.14218. Anticancer Res. 2020. PMID: 32366392

5

Eribulin regresses a doxorubicin-resistant Ewing's sarcoma with a FUS-ERG fusion and CDKN2A-deletion in a patient-derived orthotopic xenograft (PDOX) nude mouse model.

Miyake K, Murakami T, Kiyuna T, Igarashi K, Kawaguchi K, Li Y, Singh AS, Dry SM, Eckardt MA, Hiroshima Y, Momiyama M, Matsuyama R, Chishima T, Endo I, Eilber FC, Hoffman RM. Miyake K, et al. J Cell Biochem. 2018 Jan;119(1):967-972. doi: 10.1002/jcb.26263. Epub 2017 Sep 12. J Cell Biochem. 2018. PMID: 28681998

6

Salmonella typhimurium A1-R Exquisitely Targets and Arrests a Matrix-producing Triple-negative Breast Carcinoma in a PDOX Model.

Hamada K, Aoki Y, Yamamoto J, Hozumi C, Zhao M, Murata T, Sugisawa N, Bouvet M, Tsunoda T, Hoffman RM. Hamada K, et al. In Vivo. 2021 Nov-Dec;35(6):3067-3071. doi: 10.21873/invivo.12602. In Vivo. 2021. PMID: 34697138 Free PMC article.

7

Efficacy of Oral Recombinant Methioninase and Eribulin on a PDOX Model of Triple-negative Breast Cancer (TNBC) Liver Metastasis.

Lim HI, Sun YU, Han Q, Yamamoto J, Hoffman RM. Lim HI, et al. In Vivo. 2021 Sep-Oct;35(5):2531-2534. doi: 10.21873/invivo.12534. In Vivo. 2021. PMID: 34410939 Free PMC article.

8

Eribulin Suppressed Cisplatinum- and Doxorubicin-resistant Recurrent Lung Metastatic Osteosarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.

Kiyuna T, Tome Y, Miyake K, Murakami T, Oshiro H, Igarashi K, Kawaguchi K, Hsu J, Singh M, Li Y, Nelson S, Bouvet M, Singh SR, Kanaya F, Hoffman RM. Kiyuna T, et al. Anticancer Res. 2019 Sep;39(9):4775-4779. doi: 10.21873/anticanres.13661. Anticancer Res. 2019. PMID: 31519578

9

Eribulin Regresses a Doxorubicin-resistant Dedifferentiated Liposarcoma in a Patient-derived Orthotopic Xenograft Mouse Model.

Igarashi K, Kawaguchi K, Kiyuna T, Miyake K, Higuchi T, Yamamoto N, Hayashi K, Kimura H, Miwa S, Singh SR, Tsuchiya H, Hoffman RM. Igarashi K, et al. Cancer Genomics Proteomics. 2020 Jul-Aug;17(4):351-358. doi: 10.21873/cgp.20194. Cancer Genomics Proteomics. 2020. PMID: 32576580 Free PMC article.

10

Radiosensitization with combined use of olaparib and PI-103 in triple-negative breast cancer.

Jang NY, Kim DH, Cho BJ, Choi EJ, Lee JS, Wu HG, Chie EK, Kim IA. Jang NY, et al. BMC Cancer. 2015 Mar 3;15:89. doi: 10.1186/s12885-015-1090-7. BMC Cancer. 2015. PMID: 25884663 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

194 results

Results by year